NEULAND LAB Latest Share Price (NEULANDLAB)
TODAY IN ONE LINE
NEULANDLAB fell 1.1% on average volume, in line with Nifty's -0.3% move.
With a market cap of ₹30,060.43 Cr., it trades at a P/E of 60.39. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NEULAND LAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 664.4% YoY
- ●High Capital EfficiencyROCE of 19.2% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.5%
- ●Healthy Operating MarginsOPM is structurally strong at 25.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.11x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 66.3x
- ●Promoter Pledging DetectedPledge activity recorded on 26-Mar-2026 15:54
Latest NEULAND LAB News
What changed recently?
Recent events, corporate actions, and announcements.
NEULAND LAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NEULAND LAB, framed against the sector median so the premium or discount is obvious at a glance.
NEULAND LAB trades at a P/E of 60.39× and P/B of 16.04×, against the Healthcare sector median P/E of 46.02×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
NEULAND LAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NEULAND LAB — derived from the latest tape, not yesterday's close.
NEULAND LAB last traded at ₹23,535 with an intraday range of ₹23,225–₹23,895 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹23535.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 25218.33 | +1683.33 | +7.15% |
| R3 | 24548.33 | +1013.33 | +4.31% |
| R2 | 24221.67 | +686.67 | +2.92% |
| R1 | 23878.33 | +343.33 | +1.46% |
| PIVOT | 23551.67 | 16.67 | 0.07% |
| CURRENT | 23535.00 | — | — |
| S1 | 23208.33 | -326.67 | -1.39% |
| S2 | 22881.67 | -653.33 | -2.78% |
| S3 | 22538.33 | -996.67 | -4.23% |
| S4 | 21868.33 | -1666.67 | -7.08% |
NEULANDLAB is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹23225–₹23780
Trading Inside opening range
NEULAND LAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for NEULAND LAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
NEULAND LAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹30,060.43 Cr. and reported EPS of ₹115.10.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,477 | 2,023 ▲ 37.0% |
| Sales Growth YoY %Derived | -5.24% | 36.98% |
| Other Income | 21 | 30 ▲ 47.1% |
| Total Income | 1,497 | 2,053 ▲ 37.1% |
| 588 | 756 ▲ 28.6% | |
| Gross ProfitDerived | 889 | 1,267 ▲ 42.5% |
| Gross Margin %Derived | 60.21% | 62.65% |
| 566 | 693 ▲ 22.4% | |
| EBITDA (Operating Profit)Derived | 323 | 574 ▲ 77.7% |
| OPM %Derived | 21.89% | 28.40% |
| 150 | 116 ▼ 23.0% | |
| Profit Before Tax (PBT) | 346 | 489 ▲ 41.2% |
| 86 | 125 ▲ 45.0% | |
| Effective Tax %Derived | 24.90% | 25.56% |
| Total Profit for Period | 260 | 364 ▲ 39.9% |
| Net Profit (Owner's PAT)Derived | 260 | 364 ▲ 39.9% |
| Net Profit Margin %Derived | 17.61% | 17.99% |
| PAT Growth YoY %Derived | -13.32% | 39.94% |
| Earnings Per Share (EPS ₹) | 202.74 | 283.71 ▲ 39.9% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | 1 ▲ 2475.2% |
| Total Expenses (incl. D&A & Interest) | 1,151 | 1,564 ▲ 35.9% |
| Material Cost % of RevenueDerived | 38.92% | 40.52% |
| Employee Cost % of RevenueDerived | 18.42% | 16.86% |
| Other Cost % of RevenueDerived | 19.90% | 17.39% |
| Interest Coverage (x)Derived | 31.06x | 20.16x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 667 | 763 ▲ 14.4% | 937 ▲ 22.8% | 951 ▲ 1.5% | 1,191 ▲ 25.2% | 1,559 ▲ 30.8% | 1,477 ▼ 5.2% | 2,023 ▲ 37.0% | |
| Sales Growth YoY %Derived | — | 14.38% | 22.84% | 1.51% | 25.25% | 30.84% | -5.24% | 36.98% | |
| Other Income | 3 | 4 ▲ 11.3% | 16 ▲ 314.2% | 2 ▼ 87.1% | 10 ▲ 369.4% | 13 ▲ 28.7% | 21 ▲ 63.5% | 30 ▲ 47.1% | |
| Total Income | 670 | 767 ▲ 14.4% | 953 ▲ 24.3% | 953 ▲ 0.0% | 1,201 ▲ 26.0% | 1,571 ▲ 30.8% | 1,497 ▼ 4.7% | 2,053 ▲ 37.1% | |
366 | 380 ▲ 3.8% | 438 ▲ 15.3% | 422 ▼ 3.7% | 478 ▲ 13.3% | 577 ▲ 20.7% | 588 ▲ 1.8% | 756 ▲ 28.6% | ||
| Gross ProfitDerived | 301 | 383 ▲ 27.3% | 499 ▲ 30.3% | 529 ▲ 6.1% | 713 ▲ 34.8% | 981 ▲ 37.6% | 889 ▼ 9.4% | 1,267 ▲ 42.5% | |
| Gross Margin %Derived | 45.08% | 50.15% | 53.21% | 55.61% | 59.85% | 62.96% | 60.21% | 62.65% | |
242 | 281 ▲ 15.9% | 352 ▲ 25.3% | 386 ▲ 9.8% | 441 ▲ 14.2% | 519 ▲ 17.6% | 566 ▲ 9.1% | 693 ▲ 22.4% | ||
| EBITDA (Operating Profit)Derived | 58 | 102 ▲ 74.6% | 147 ▲ 44.1% | 143 ▼ 2.9% | 272 ▲ 90.6% | 463 ▲ 70.2% | 323 ▼ 30.1% | 574 ▲ 77.7% | |
| OPM %Derived | 8.75% | 13.36% | 15.67% | 15.00% | 22.82% | 29.68% | 21.89% | 28.40% | |
42 | 53 ▲ 27.3% | 58 ▲ 8.9% | 63 ▲ 8.6% | 66 ▲ 5.3% | 74 ▲ 11.9% | 150 ▲ 103.9% | 116 ▼ 23.0% | ||
| Profit Before Tax (PBT) | 20 | 53 ▲ 160.2% | 105 ▲ 99.0% | 82 ▼ 22.0% | 216 ▲ 162.6% | 401 ▲ 86.1% | 346 ▼ 13.7% | 489 ▲ 41.2% | |
4 | 37 ▲ 842.4% | 25 ▼ 32.7% | 18 ▼ 25.8% | 52 ▲ 184.8% | 101 ▲ 94.1% | 86 ▼ 14.9% | 125 ▲ 45.0% | ||
| Effective Tax %Derived | 19.16% | 69.37% | 23.45% | 22.32% | 24.21% | 25.25% | 24.90% | 25.56% | |
| Total Profit for Period | 16 | 16 ▼ 1.4% | 81 ▲ 397.4% | 64 ▼ 20.8% | 164 ▲ 156.2% | 300 ▲ 83.5% | 260 ▼ 13.3% | 364 ▲ 39.9% | |
| Net Profit (Owner's PAT)Derived | 16 | 16 ▼ 1.4% | 81 ▲ 397.4% | 64 ▼ 20.8% | 164 ▲ 156.2% | 300 ▲ 83.5% | 260 ▼ 13.3% | 364 ▲ 39.9% | |
| Net Profit Margin %Derived | 2.47% | 2.13% | 8.61% | 6.71% | 13.73% | 19.25% | 17.61% | 17.99% | |
| PAT Growth YoY %Derived | — | -1.41% | 397.40% | -20.85% | 156.21% | 83.51% | -13.32% | 39.94% | |
| Earnings Per Share (EPS ₹) | 12.82 | 12.63 ▼ 1.5% | 62.85 ▲ 397.6% | 49.74 ▼ 20.9% | 127.45 ▲ 156.2% | 233.89 ▲ 83.5% | 202.74 ▼ 13.3% | 283.71 ▲ 39.9% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 236.6% | -2 ▼ 260.5% | -6 ▼ 279.0% | -4 ▲ 40.9% | 1 ▲ 138.8% | -0 ▼ 103.3% | 1 ▲ 2475.2% | |
| Total Expenses (incl. D&A & Interest) | 650 | 714 ▲ 9.8% | 848 ▲ 18.8% | 871 ▲ 2.8% | 985 ▲ 13.1% | 1,170 ▲ 18.7% | 1,151 ▼ 1.6% | 1,564 ▲ 35.9% | |
| Material Cost % of RevenueDerived | 54.05% | 51.31% | 46.93% | 46.01% | 40.94% | 40.58% | 38.92% | 40.52% | |
| Employee Cost % of RevenueDerived | 16.56% | 16.20% | 15.98% | 19.19% | 16.94% | 16.49% | 18.42% | 16.86% | |
| Other Cost % of RevenueDerived | 19.76% | 20.59% | 21.55% | 21.43% | 20.09% | 16.79% | 19.90% | 17.39% | |
| Interest Coverage (x)Derived | 2.08x | 3.27x | 5.99x | 6.93x | 16.76x | 28.78x | 31.06x | 20.16x |
NEULAND LAB segment analysis : revenue and profit mix.
Disclosed business segments at NEULAND LAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
NEULAND LAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NEULAND LAB.
Our AI distills the core fundamental drivers supporting NEULAND LAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
NEULAND LAB's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 79 (~1.7× the sector multiple of 46.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 14% would indicate weaker capital compounding.
NEULAND LAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NEULAND LAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NEULAND LAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NEULAND LAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
NEULAND LAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NEULAND LAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NEULAND LAB stood at 45.8% of traded volume, against a 20-day average of 46.5%.
NEULAND LAB announcements: results, concalls, ratings, M&A.
Filings NEULAND LAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NEULAND LAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 173 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
Updates
Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'.
Credit Rating
Neuland Laboratories Limited has informed the Exchange about Credit Rating
Copy of Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Neuland Laboratories Limited has informed the Exchange regarding 'Intimation Regarding Completion Of US FDA Inspection'.
Investor decks & rating reports.
NEULAND LAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NEULAND LAB has declared, sequenced by announce and record date.
NEULAND LAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
NEULAND LAB insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in NEULAND LAB as reported to SEBI — buying and selling signals from the people who know the business best.
NEULAND LAB insider activity below tracks 12 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr. | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Deepthi Davuluri | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Davuluri Ownership Trust | Insider | 28 Feb 2025 | buy | +79.5 K | — | — |
| Saharsh Rao Davuluri | Insider | 28 Feb 2025 | sell | −79.5 K | — | — |
| Sucheth Rao Davuluri | Insider | 25 Feb 2025 | sell | −79.6 K | — | — |
| Davuluri Ownership Trust | Insider | 25 Feb 2025 | buy | +32.54 L | — | — |
About NEULAND LAB: business, sector, key facts.
What NEULAND LAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NEULAND LAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NEULANDLAB, BSE: 524558.
Neuland Laboratories Limited is a global manufacturer and supplier of active pharmaceutical ingredients (APIs). Its primary business centers around the production and distribution of these essential components used in the creation of pharmaceutical drugs. The company serves a broad international market, with operations spanning India, Europe, the United States, and other countries around the world, signifying a significant global reach and established distribution network.
A key aspect of Neuland Laboratories' business model is its provision of custom manufacturing solutions. This service allows pharmaceutical companies to outsource the production of specific APIs tailored to their unique needs and formulations. This approach offers flexibility and scalability to clients, enabling them to focus on research, development, and marketing while leveraging Neuland's manufacturing expertise and infrastructure.
Further enhancing its service portfolio, Neuland Laboratories offers specialized peptide synthesis services. Peptides are short chains of amino acids that play crucial roles in various biological processes, making them important components in a range of therapeutic applications. The company's proficiency in this area demonstrates a commitment to advanced pharmaceutical technologies and a capability to cater to the increasing demand for complex pharmaceutical molecules.
Established in 1984 and headquartered in Hyderabad, India, Neuland Laboratories has a long history in the pharmaceutical industry. This long-standing presence suggests experience in navigating regulatory landscapes, managing complex production processes, and building strong relationships with clients and regulatory bodies across different global markets. The company’s sustained operation and global footprint highlight its ability to adapt and thrive in a dynamic and competitive industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about NEULAND LAB (NEULANDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NEULAND LAB (NEULANDLAB)?
The current share price of NEULAND LAB (NEULANDLAB) is ₹23,535.00. Today, the stock has declined by ₹265.00 (1.11%), trading in a range of ₹23,225.00 to ₹23,895.00. The stock opened at ₹23,780.00 with a trading volume of 43,901 shares.
02Is NEULAND LAB stock a good investment for long-term?
NEULAND LAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹30,060.43 Cr., P/E ratio of 60.39, ROE of 19.46%, and ROCE of 19.17%. The dividend yield stands at 0.15%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NEULAND LAB stock?
The 52-week high price of NEULAND LAB (NEULANDLAB) is ₹24,225.00, while the 52-week low is ₹11,500.00. Currently trading at ₹23,535.00, the stock is 104.65% above its 52-week low and 2.85% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NEULAND LAB stock at the current price?
Whether to buy NEULAND LAB stock at ₹23,535.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 60.39 and P/B ratio of 16.04. Today's performance shows a loss of 1.11%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NEULAND LAB and when is the next dividend?
NEULAND LAB offers a dividend yield of 0.15%, which means for every ₹100 invested at the current price of ₹23,535.00, you can expect to receive approximately ₹0.15 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NEULAND LAB?
NEULAND LAB's key financial metrics include: P/E Ratio: 60.39, P/B Ratio: 16.04, ROE: 19.46%, ROCE: 19.17%, Dividend Yield: 0.15%, EPS: ₹115.10, Book Value: ₹1,461.02, and Debt-to-Equity: 0.11. The company's market cap stands at ₹30,060.43 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NEULAND LAB stock performing today in the market?
NEULAND LAB stock opened at ₹23,780.00 and is currently trading at ₹23,535.00, showing a decline of ₹265.00 (1.11%). The intraday high is ₹23,895.00 and low is ₹23,225.00. The trading volume stands at 43,901 shares, indicating moderate market participation today.
08What is the P/E ratio of NEULAND LAB and what does it indicate?
NEULAND LAB has a Price-to-Earnings (P/E) ratio of 60.39, which means investors are willing to pay 60.39 for every ₹1 of earnings. With an EPS of ₹115.10, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NEULAND LAB (NEULANDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.